A Long-Term Study of a Lipid-Buprenorphine Implant in Rats
Author(s) -
Michael Guarnieri,
Cory Brayton,
Betty Tyler
Publication year - 2018
Publication title -
journal of veterinary medicine
Language(s) - English
Resource type - Journals
eISSN - 2356-7708
pISSN - 2314-6966
DOI - 10.1155/2018/2616152
Subject(s) - urinalysis , buprenorphine , medicine , drug , triglyceride , hematology , cholesterol , histopathology , pharmacology , implant , anesthesia , surgery , opioid , pathology , receptor , urine
Animal models to study opiates are of growing interest. We have examined the short-term safety of buprenorphine implants in Fischer F344/NTac rats treated with excess doses of a cholesterol-triglyceride suspension of buprenorphine. A single injection of 0.65 mg/kg afforded clinically significant blood levels of analgesia for 3 days. Chemistry, hematology, coagulation, and urinalysis values with 2- to 10-fold excess doses of the drug-lipid suspension were within normal limits. Histopathology findings were unremarkable. The skin and underlying tissue surrounding the drug injection were unremarkable. Here we report the results of a long-term follow-up study of female rats injected with 0.65 and 1.3 mg/kg. The 14-month evaluation showed no abnormal findings that could be attributed to the drug or lipid suspension. These results confirm the safety of cholesterol-triglyceride carrier systems for subcutaneous drug delivery in laboratory animals and suggest that this model may be used to study long-term effects of opiate therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom